159 related articles for article (PubMed ID: 18453862)
1. Does tenofovir increase efavirenz hepatotoxicity?
Lattuada E; Lanzafame M; Carolo G; Gottardi M; Concia E; Vento S
AIDS; 2008 May; 22(8):995. PubMed ID: 18453862
[No Abstract] [Full Text] [Related]
2. Efavirenz + emtricitabine + tenofovir: new combination. HIV infection: do not modify ongoing therapy just to use one less tablet. Better adherence than with separate dosing has not been demonstrated, while reduced efficacy is plausible.
Prescrire Int; 2009 Jun; 18(101):105. PubMed ID: 19637416
[No Abstract] [Full Text] [Related]
3. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.
Gulick RM; Lalama CM; Ribaudo HJ; Shikuma CM; Schackman BR; Schouten J; Squires KE; Koletar SL; Pilcher CD; Reichman RC; Klingman KL; Kuritzkes DR
AIDS; 2007 Apr; 21(7):813-23. PubMed ID: 17415036
[TBL] [Abstract][Full Text] [Related]
4. [Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
Bayonne Kombo ES; Gathse A
Med Mal Infect; 2013 Mar; 43(3):134-5. PubMed ID: 23434355
[No Abstract] [Full Text] [Related]
5. Tenofovir-related nephrotoxicity in HIV-infected patients.
Barrios A; García-Benayas T; González-Lahoz J; Soriano V
AIDS; 2004 Apr; 18(6):960-3. PubMed ID: 15060449
[No Abstract] [Full Text] [Related]
6. A tailored dose of tenofovir could reduce its impact on bone mass in HIV Type 1-infected children and adolescents: a report from 5 years of clinical experience.
Rosso R; Parodi A; Torrisi C; De Terlizzi F; Viscoli C; Vignolo M
AIDS Res Hum Retroviruses; 2010 Dec; 26(12):1265-6. PubMed ID: 20874420
[No Abstract] [Full Text] [Related]
7. The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy.
Madruga JR; Cassetti I; Suleiman JM; Etzel A; Zhong L; Holmes CB; Cheng AK; Enejosa J;
HIV Clin Trials; 2007; 8(6):381-90. PubMed ID: 18042503
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of simplification therapy with once-daily tenofovir, lamivudine, and efavirenz in HIV-1-infected patients with undetectable plasma viral load on HAART.
Arrizabalaga J; Arazo P; Aguirrebengoa K; García-Palomo D; Chocarro A; Labarga P; Muñoz-Sánchez MJ; Echevarría S; Oteo JA; Uriz J; Letona S; Fariñas MC; Peralta G; Pinilla J; Ferrer P; Alvarez ML; Iribarren JA
HIV Clin Trials; 2007; 8(5):328-36. PubMed ID: 17956834
[TBL] [Abstract][Full Text] [Related]
9. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients.
Cassetti I; Madruga JV; Suleiman JM; Etzel A; Zhong L; Cheng AK; Enejosa J;
HIV Clin Trials; 2007; 8(3):164-72. PubMed ID: 17621463
[TBL] [Abstract][Full Text] [Related]
10. [Two cases of Fanconi's syndrome induced by tenofovir in the Ivory Coast].
Ondounda M; Tanon A; Ehui E; Ouattara I; Kassi A; Aba YT; Aoussi EF; Kakou AR; Eholié SP; Bissagnene E; Kadio A
Med Mal Infect; 2011 Feb; 41(2):105-7. PubMed ID: 20832214
[No Abstract] [Full Text] [Related]
11. Safety and efficacy of tenofovir/emtricitabine or abacavir/lamivudine in combination with efavirenz in treatment naïve HIV patients: a 5 year retrospective observational cohort study. (the TOKEN Study).
Pammi M; Arumainayagam J; Kumari B; Ahmed-Jushuf I; Carlin EM; Chandramani S; Riddell L; Ghanem M; Das S
Int J Clin Pract; 2013 Sep; 67(9):922-3. PubMed ID: 23952469
[No Abstract] [Full Text] [Related]
12. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
Gallant JE; DeJesus E; Arribas JR; Pozniak AL; Gazzard B; Campo RE; Lu B; McColl D; Chuck S; Enejosa J; Toole JJ; Cheng AK;
N Engl J Med; 2006 Jan; 354(3):251-60. PubMed ID: 16421366
[TBL] [Abstract][Full Text] [Related]
13. CYP2B6 haplotype and biological factors responsible for hepatotoxicity in HIV-infected patients receiving efavirenz-based antiretroviral therapy.
Manosuthi W; Sukasem C; Lueangniyomkul A; Mankatitham W; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
Int J Antimicrob Agents; 2014 Mar; 43(3):292-6. PubMed ID: 24359841
[TBL] [Abstract][Full Text] [Related]
14. Acute tubular necrosis in a patient receiving tenofovir.
Lee JC; Marosok RD
AIDS; 2003 Nov; 17(17):2543-4. PubMed ID: 14600530
[No Abstract] [Full Text] [Related]
15. The rate of recovery in renal function when patients with HIV infection discontinue treatment with tenofovir.
Young J; Wang Q; Fux CA; Bernasconi E; Furrer H; Vernazza P; Calmy A; Cavassini M; Weber R; Battegay M; Bucher HC;
HIV Med; 2014 Sep; 15(8):505-10. PubMed ID: 24641488
[TBL] [Abstract][Full Text] [Related]
16. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
Molina JM; Cahn P; Grinsztejn B; Lazzarin A; Mills A; Saag M; Supparatpinyo K; Walmsley S; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
Lancet; 2011 Jul; 378(9787):238-46. PubMed ID: 21763936
[TBL] [Abstract][Full Text] [Related]
17. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.
Rockstroh JK; Lennox JL; Dejesus E; Saag MS; Lazzarin A; Wan H; Walker ML; Xu X; Zhao J; Teppler H; Dinubile MJ; Rodgers AJ; Nguyen BY; Leavitt R; Sklar P;
Clin Infect Dis; 2011 Oct; 53(8):807-16. PubMed ID: 21921224
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for CD4 lymphopenia in patients treated with a tenofovir/didanosine high dose-containing highly active antiretroviral therapy regimen.
Lacombe K; Pacanowski J; Meynard JL; Trylesinski A; Girard PM
AIDS; 2005 Jul; 19(10):1107-8. PubMed ID: 15958845
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
Aurpibul L; Cressey TR; Sricharoenchai S; Wittawatmongkol O; Sirisanthana V; Phongsamart W; Sudjaritruk T; Chokephaibulkit K
Pediatr Infect Dis J; 2015 Apr; 34(4):392-7. PubMed ID: 25760566
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1.
Gallien S; Flandre P; Nguyen N; De Castro N; Molina JM; Delaugerre C
J Med Virol; 2015 Feb; 87(2):187-91. PubMed ID: 25070158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
